Emcure Pharmaceuticals Ltd (NSE:EMCURE) — Stock Price
Emcure Pharmaceuticals Ltd (NSE:EMCURE) is currently trading at Rs1995.20 INR, up 0.85% today. Over the past 52 weeks, shares have ranged between Rs1271.80 and Rs1995.20. This page tracks Emcure Pharmaceuticals Ltd's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Emcure Pharmaceuticals Ltd (EMCURE) total market value.
Emcure Pharmaceuticals Ltd (EMCURE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Emcure Pharmaceuticals Ltd's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Emcure Pharmaceuticals Ltd Income Statement — Revenue, Profit & Earnings by Year
Emcure Pharmaceuticals Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Revenue | Rs92.04 Billion | Rs78.08 Billion | Rs65.82 Billion | Rs59.31 Billion | Rs57.66 Billion |
| Cost of Revenue | Rs56.24 Billion | Rs639.08 Million | Rs26.10 Billion | Rs24.08 Billion | Rs23.94 Billion |
| Gross Profit | Rs35.79 Billion | Rs275.05 Million | Rs39.72 Billion | Rs35.23 Billion | Rs33.72 Billion |
| Research & Development | — | — | — | — | — |
| SG&A | — | Rs2.45 Billion | Rs7.74 Billion | Rs6.45 Billion | Rs5.73 Billion |
| Total Operating Expenses | Rs22.06 Billion | Rs34.01 Billion | Rs56.65 Billion | Rs49.90 Billion | Rs46.79 Billion |
| Operating Income | Rs13.74 Billion | Rs10.85 Billion | Rs9.17 Billion | Rs9.41 Billion | Rs10.87 Billion |
| EBITDA | Rs13.74 Billion | Rs14.95 Billion | — | — | — |
| EBIT | — | Rs11.11 Billion | — | — | — |
| Interest Expense | Rs1.44 Billion | Rs1.40 Billion | Rs2.01 Billion | Rs1.63 Billion | Rs1.32 Billion |
| Income Before Tax | Rs12.87 Billion | Rs9.71 Billion | Rs7.27 Billion | Rs7.47 Billion | Rs9.73 Billion |
| Income Tax Expense | Rs3.46 Billion | Rs30.85 Million | — | — | — |
| Net Income | Rs9.24 Billion | Rs6.81 Billion | Rs4.98 Billion | Rs5.32 Billion | Rs6.62 Billion |
Emcure Pharmaceuticals Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Emcure Pharmaceuticals Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Assets | Rs96.12 Billion | Rs82.33 Billion | Rs78.06 Billion | Rs66.73 Billion | Rs60.63 Billion |
| Total Current Assets | Rs56.12 Billion | Rs45.56 Billion | Rs42.60 Billion | Rs38.36 Billion | Rs34.24 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | Rs760.43 Million | Rs2.89 Billion | Rs2.04 Billion | Rs1.46 Billion |
| Net Receivables | Rs25.63 Billion | Rs20.55 Billion | Rs18.59 Billion | Rs16.48 Billion | Rs13.09 Billion |
| Inventory | Rs23.98 Billion | Rs19.32 Billion | Rs15.25 Billion | Rs13.83 Billion | Rs14.49 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | Rs4.14 Billion | Rs3.68 Billion | Rs3.79 Billion | Rs2.18 Billion | Rs2.17 Billion |
| Total Liabilities | Rs46.36 Billion | Rs35.91 Billion | Rs46.84 Billion | Rs40.23 Billion | Rs39.49 Billion |
| Total Current Liabilities | Rs39.12 Billion | Rs26.68 Billion | Rs32.10 Billion | Rs30.19 Billion | Rs29.65 Billion |
| Long-term Debt | — | Rs1.90 Billion | Rs7.67 Billion | Rs7.44 Billion | Rs7.17 Billion |
| Net Debt | Rs11.22 Billion | Rs9.01 Billion | Rs19.78 Billion | Rs21.39 Billion | Rs20.08 Billion |
| Total Stockholder Equity | Rs49.50 Billion | Rs44.46 Billion | Rs29.52 Billion | Rs25.01 Billion | Rs19.88 Billion |
| Retained Earnings | — | Rs33.13 Billion | Rs26.34 Billion | Rs21.96 Billion | Rs16.95 Billion |
Emcure Pharmaceuticals Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Emcure Pharmaceuticals Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs8.51 Billion | Rs8.52 Billion | Rs10.97 Billion | Rs7.47 Billion | Rs7.68 Billion |
| Capital Expenditures | Rs3.61 Billion | Rs4.07 Billion | Rs3.07 Billion | Rs4.03 Billion | Rs3.97 Billion |
| Free Cash Flow | Rs4.90 Billion | Rs4.45 Billion | Rs7.90 Billion | Rs3.43 Billion | Rs3.71 Billion |
| Investing Cash Flow | Rs-11.95 Billion | Rs-940.01 Million | — | — | — |
| Financing Cash Flow | Rs4.38 Billion | Rs-8.14 Billion | — | — | — |
| Dividends Paid | Rs-568.53 Million | — | Rs542.55 Million | Rs361.70 Million | Rs542.55 Million |
| Stock-Based Compensation | — | Rs19.89 Million | Rs39.67 Million | Rs52.76 Million | Rs57.16 Million |
| Depreciation | Rs4.15 Billion | Rs3.84 Billion | Rs3.12 Billion | Rs2.60 Billion | Rs2.45 Billion |
| Change in Cash | Rs-80.15 Million | Rs-583.02 Million | Rs2.21 Billion | Rs1.34 Billion | Rs-1.72 Billion |
Emcure Pharmaceuticals Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Emcure Pharmaceuticals Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 14.70 | 13.60 | +8.09% |
| Feb 04, 2026 | 13.67 | 10.80 | +26.57% |
| Nov 11, 2025 | 12.85 | 12.00 | +7.08% |
| Aug 07, 2025 | 11.06 | 9.90 | +11.72% |
| May 22, 2025 | 10.38 | 10.10 | +2.77% |
| Feb 06, 2025 | 8.12 | 9.60 | -15.42% |
| Nov 07, 2024 | 10.33 | 8.80 | +17.39% |